SOHO Highlights: State of the Art and Next Questions


 

CML State of the Art: Dasatinib/Imatinib Dose Optimization, STAMPi Asciminib Efficacy in CP-CML, Treatment Free Remission, Single Cell Analysis

62 views
February 5, 2021
Comments 0
Login to view comments. Click here to Login